![]() Article ID: 708314 T-cell receptor diversity may be key to treatment of follicular lymphoma, Mayo study findsMayo ClinicHealthy white blood cells, called “T-cells,” play a crucial role in how the body fights follicular lymphoma. That's according to the results of a study led by Mayo Clinic hematologists Zhi Zhang Yang, M.D., and Stephen Ansell, M.D., Ph.D., that was published in Cell Reports. T-cells are a key part of the immune system and protect the body by fighting infections and cancer. Released:19-Feb-2019 1:05 PM EST |
Embargo will expire:21-Feb-2019 12:05 AM ESTReleased to reporters:19-Feb-2019 12:05 PM EST |
![]()
Article ID: 708023 Lupus Strongly Linked to Imbalances in Gut MicrobiomeNYU Langone HealthThe disease systemic lupus erythematosus (SLE) — marked by the attack on joints, skin, and kidneys by the body’s immune system — is linked to an abnormal mix of bacteria in the gut. This is according to a new study led by scientists at NYU School of Medicine. Released:13-Feb-2019 11:05 AM EST |
Embargo will expire:20-Feb-2019 2:00 PM ESTReleased to reporters:18-Feb-2019 10:05 PM EST |
Embargo will expire:20-Feb-2019 2:00 PM ESTReleased to reporters:18-Feb-2019 2:00 PM EST |
Article ID: 708182 Small cell lung cancer may respond to combination of immunotherapy and DNA damage repair inhibitorsUniversity of Texas M. D. Anderson Cancer CenterResearchers at The University of Texas MD Anderson Cancer Center have discovered that a combination of immune checkpoint blockade and targeted therapies that block normal DNA damage repair (DDR) achieved significant tumor regression in mouse models of small cell lung cancer (SCLC), suggesting a promising new approach for treating patients with this aggressive cancer. Released:17-Feb-2019 12:05 AM EST |
Article ID: 708091 Drug combination may become new standard treatment for advanced kidney cancerDana-Farber Cancer InstituteA combination of two drugs – one of them an immunotherapy agent – could become a new standard, first-line treatment for patients with metastatic kidney cancer, says an investigator from Dana-Farber Cancer Institute, reporting results from a phase 3 clinical trial. Released:15-Feb-2019 2:05 PM EST |
![]() Article ID: 708176 Why Some Brain Tumors Respond to ImmunotherapyColumbia University Irving Medical CenterFewer than 1 in 10 patients with glioblastoma—the most common type of brain cancer—respond to immunotherapy; a new study reveals how to detect patients who may respond. Released:15-Feb-2019 11:05 AM EST |
![]() Article ID: 708137 This Immune Cell Function Could Control Deadly Allergic ReactionsMichigan State UniversityMichigan State University scientists have identified a master control mechanism on mast cells, a type of immune cell, that can prevent the immune system from overreacting in times of stress, potentially limiting, or even stopping allergic reactions from happening. Released:14-Feb-2019 4:05 PM EST |
![]() Article ID: 708133 Immune Profiling: A New Opportunity for Drug DevelopmentPerelman School of Medicine at the University of PennsylvaniaCollectively, assessing a snapshot of a person’s unique state of immune health is called immune profiling, which can entail identifying immune-cell-associated genes and proteins, as well as the cell types themselves. Released:14-Feb-2019 3:05 PM EST |